<DOC>
	<DOC>NCT01680991</DOC>
	<brief_summary>This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety of obinutuzumab in participants with cluster of differentiation (CD) 20 positive (+) malignant disease. Participants will receive multiple doses of obinutuzumab. The anticipated time on study treatment is 24 weeks.</brief_summary>
	<brief_title>A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Diagnosis of CD20+ Bcell lymphoma or BCLL Refractory/relapsed CLL, FL, and DLBCL At least 1 measurable lesion (greater than [&gt;] 1.5 centimeters [cm] in its largest dimension) with the exception of CLL Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Life expectancy &gt;6 months Prior use of any investigational antibody therapy within 6 months of study start Prior use of any anticancer vaccine Prior administration of rituximab within 3 months of study start Prior administration of radioimmunotherapy 3 months prior to study entry Central nervous system lymphoma History of other malignancy Evidence of significant, uncontrolled concomitant disease Abnormal laboratory values Patients with progressive multifocalleukoencephalopathy (PML) Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>